Lever
Lifestyle
- increase physical activity
- maintain healthy weight
- reduce alcohol intake
Blutwerte · Marker
Non-HDL-Cholesterin
Non-HDL Cholesterol · Non-HDL-C
Lipide & Herz-Kreislauf
- Einheit:
- mmol/L
- Abbreviation
- Non-HDL-C
Non-HDL-Cholesterin measures the total cholesterol content of all atherogenic lipoproteins, excluding HDL.
Reference Ranges
Reference
0–3.9mmol/L
0
3.5
3.9
LowNormalHigh
Reference
Optimal
Unit · mmol/LNon-fasting samples are acceptable; values ≥3.9 mmol/L are flagged as abnormal.
Overview
Übersicht
Non-HDL-Cholesterin (Non-HDL-C) is a blood biomarker that represents the total cholesterol content of all atherogenic lipoproteins, excluding high-density lipoprotein (HDL). It is calculated by subtracting HDL cholesterol from total cholesterol. Researchers found that Non-HDL-C is a robust predictor of cardiovascular disease (CVD) risk as it encompasses all lipoproteins that contribute to atherosclerosis, including LDL, VLDL, and intermediate-density lipoproteins. Clinically, elevated Non-HDL-C levels are associated with increased risk of coronary artery disease and peripheral vascular disease, making it a critical marker in assessing cardiovascular health. For athletes and biohackers, maintaining optimal Non-HDL-C levels may be important for cardiovascular efficiency and longevity. While fasting is traditionally required for lipid profiles, researchers observed that Non-HDL-C levels are not significantly affected by fasting status, allowing for more flexible testing. However, factors such as genetic predispositions, lifestyle, and metabolic conditions can influence Non-HDL-C levels, necessitating a comprehensive approach to interpretation.
Klinische Bedeutung
Elevated Non-HDL-C levels indicate increased risk for cardiovascular diseases, including coronary artery disease and peripheral vascular disease. Reduced levels are generally not a concern but may reflect underlying metabolic issues if significantly low.
Dynamics
Trend Interpretation
Rising Values
Progressively rising values suggest worsening lipid profile and increased cardiovascular risk. Re-test in 3-6 months.
Falling Values
Progressively falling values indicate improvement in lipid management and reduced cardiovascular risk.
Re-test Interval
6 months if outside optimal range
Etiology
Causes — High & Low
Cause
Elevated Levels
- poor diet
- sedentary lifestyle
- genetic predisposition
- metabolic syndrome
- hypothyroidism
- chronic kidney disease
Cause
Low Levels
- hyperthyroidism
- malabsorption syndromes
- liver disease
- severe malnutrition
Protocol
How to Optimize
Lever
Nutrition
- increase fiber intake
- consume omega-3 fatty acids
- reduce saturated fat
Lever
Supplementation
- omega-3 supplements
- plant sterols
- niacin
Note:
Consult healthcare provider before starting supplements, especially if on medication.
Testing Guidelines
✓Fasting Not Required
✓Not Time-Sensitive
Testing Frequency
Annually for adults, more frequent if at risk for CVD.
Interfering Factors
- recent high-fat meal
- acute illness
- pregnancy
Related Peptides & Hormones
Apolipoprotein B
hormone or peptideCorrelated with
Open Research Questions
Current research suggests that reference ranges and optimal targets for non-HDL cholesterol remain debated, particularly in diverse populations, as evidenced by varying prevalence rates of dyslipidemia. Researchers have not yet established standardized diagnostic pathways for conditions like dysbetalipoproteinemia that utilize non-HDL cholesterol effectively. Additionally, unanswered clinical questions include the long-term implications of non-fasting lipid profiles on cardiovascular risk assessment and the role of non-HDL cholesterol in guiding therapeutic interventions.
23 Research Publications
1,163
Total Citations
9
Human/RCT
5.0
Avg. Influence
2025
Latest
Sort
Filter
01Top
#01
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine.
Nordestgaard Børge G, et al. · European heart journal · 2016
ReviewInfluence29.0
805
This study examined the clinical implications of using non-fasting lipid profiles instead of fasting ones. Researchers found that non-fasting measurements of non-HDL cholesterol are comparable to fasting measurements and can improve patient compliance. They recommended routine use of non-fasting lipid profiles for assessing cardiovascular risk.
Key findings
- 01Researchers observed that changes in lipid levels after eating are minimal and not clinically significant.
- 02They found that non-fasting and fasting lipid profiles can predict cardiovascular disease risk similarly.
- 03The study suggests flagging abnormal lipid levels in lab reports to help identify potential health issues.
02Top
#02
Ezetimibe: cholesterol lowering and beyond.
ReviewInfluence4.0
150
This study focused on the cholesterol-lowering effects of ezetimibe. Researchers found that ezetimibe not only lowers LDL cholesterol but also positively affects other lipid parameters, including non-HDL cholesterol and apolipoprotein B. They noted that further clinical studies are ongoing to evaluate its overall impact on cardiovascular risk.
03Top
#03
LOX-1 in atherosclerotic disease.
HumanInfluence1.0
49
This study investigated the role of LOX-1 in atherosclerotic disease. Researchers found that serum levels of LOX-1 ligands correlate with carotid intima-media thickness and cardiovascular disease incidence, independent of LDL cholesterol levels. They suggested that LOX-1 could be a valuable biomarker for assessing atherosclerosis risk.
04
#04
Update on the laboratory investigation of dyslipidemias.
Review
40
Researchers reviewed the evolving role of clinical laboratories in assessing cardiovascular disease risk through lipid measurements. They highlighted non-HDL-C as a valuable alternative for evaluating lipid profiles and emphasized the need for standardization in testing methods.
05
#05
Hypertriglyceridemia in Obese Children and Adolescents.
HumanInfluence2.0
34
This study addressed hypertriglyceridemia in obese children and adolescents, linking elevated triglyceride levels to cardiometabolic risk. Researchers recommended universal lipid screening, including non-HDL-C measurements, to identify at-risk youth.
06
#06
Biomarker variability and cardiovascular disease residual risk.
ReviewInfluence3.0
20
This study reviewed the variability of biomarkers and its association with cardiovascular disease risk. Researchers found that intraindividual variability in lipoprotein levels correlates with cardiovascular outcomes, independent of average levels. They emphasized the need for standardized approaches to assess the impact of biomarker variability.
07
#07
The clinical and laboratory investigation of dysbetalipoproteinemia.
ReviewInfluence3.0
15
This study explored familial dysbetalipoproteinemia, a genetic condition linked to high cardiovascular risk. Researchers found that routine lipid profiles cannot distinguish this condition from other types of dyslipidemia, necessitating additional testing. They suggested using apolipoprotein B as a cost-effective initial screening tool.
08
#08
Non-High-Density Lipoprotein Cholesterol and Guidelines for Cholesterol Lowering in Recent History.
Review
12
Researchers reviewed the evolution of cholesterol treatment guidelines over the years, focusing on the significance of non-HDL cholesterol as a target for treatment. The article emphasizes the advantages of non-HDL cholesterol over LDL cholesterol in assessing cardiovascular risk and recommends its inclusion in laboratory reports.
09
#09
Lipoprotein Assessment in the twenty-first Century.
ReviewInfluence1.0
10
This study provided an update on the relationship between lipoproteins and cardiovascular disease. Researchers found that accurate assessment of lipoproteins is crucial for evaluating cardiovascular risk and monitoring treatment responses. They highlighted recent advances in lipid testing as important for improving patient outcomes.
10
#10
Association of non-high-density lipoprotein cholesterol-to-high-density lipoprotein cholesterol ratio (NHHR) with gout prevalence: a cross-sectional study.
HumanInfluence1.0
9
This study investigated the relationship between the non-HDL-C/HDL-C ratio and gout prevalence. Researchers found that higher NHHR levels were associated with a greater likelihood of developing gout. They indicated that NHHR could serve as a significant marker for assessing gout risk.
Publication Trend
Research publications about Non-HDL-Cholesterin over time
9totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer